2020 Trends In Pharma Asset Licensing And Deal Terms: A Survey Of Key Decision-Makers Lain Anderson TJ Bilodeau Read more
Related Practice Life Sciences & Pharma In this article, we describe some key drivers of asset value, as well as areas of alignment and divergence between parties on deal expectations. 01052021090143
Executive Insights Biotech and Pharmaceuticals Realising the Promise of Omnichannel Engagement December 16, 2022
Published Articles Mental and Behavioral Health Trip or No Trip? The Diverging Development of Psychedelic Drugs for Mental Health … December 15, 2022
Video / Webinar MedTech APAC Hospital Priorities 2022: Strategic Implications for Medtech Firms Part 3 July 29, 2022
Article Life Sciences & Pharma Advancement in Antimicrobial Resistance Management in Asia Pacific July 12, 2022
Executive Insights Biotech and Pharmaceuticals Building Clinical Trial Leadership in Biopharma October 5, 2022